These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7693228)

  • 1. Invasive meningiomas in relation to high proliferating potential.
    Suwa T; Kawano N; Kameya T; Ito H; Oka H; Yada K
    Noshuyo Byori; 1993; 10(1):63-7. PubMed ID: 7693228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCNA, Ki-67 and hTERT in residual benign meningiomas.
    Maes L; Kalala JP; Cornelissen M; De Ridder L
    In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of proliferative potential of meningiomas using PCNA LI and AgNOR counts.
    Sudha K; Karak AK; Sharma MC; Mathur M; Sarkar C
    Indian J Pathol Microbiol; 1998 Jul; 41(3):323-30. PubMed ID: 9805855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can recurrence of meningiomas be predicted?
    Kalala JP; Benoit D; De Ridder L
    Anticancer Res; 2004; 24(4):2319-24. PubMed ID: 15330178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferating cell nuclear antigen (PCNA) and nucleolar organizer regions (NORs) in benign, atypical and malignant meningiomas.
    Lee MC; Kang MW; Yang BS; Park CS; Juhng SW; Jung S; Kim JH; Kim SH; Kang SS; Lee JH
    Noshuyo Byori; 1995; 12(2):133-9. PubMed ID: 8867694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the proliferating cell nuclear antigen and clinicopathological features in intracranial meningiomas.
    Kim CH; Cheong JH; Bak KH; Kim JM; Oh SJ
    J Clin Neurosci; 2001 May; 8 Suppl 1():44-8. PubMed ID: 11386825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of preoperative dexamethasone therapy on proliferating cell nuclear antigen (PCNA) expression in comparison to other parameters in meningiomas.
    Gottschalk J; Goebel S; Jautzke G; Martin H; Zimmer C; Märzheuser-Brands S; Cervós-Navarro J
    Histol Histopathol; 1992 Oct; 7(4):653-61. PubMed ID: 1360848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary resected meningiomas: relapses and proliferation markers.
    Kalala JP; Caemaert J; De Ridder L
    In Vivo; 2004; 18(4):411-6. PubMed ID: 15369177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
    Roser F; Samii M; Ostertag H; Bellinzona M
    Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients.
    Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Romanini C
    Gynecol Oncol; 1996 Apr; 61(1):16-21. PubMed ID: 8626110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive meningioma is associated with a low expression of E-cadherin and beta-catenin.
    Utsuki S; Oka H; Sato Y; Kawano N; Tsuchiya B; Kobayashi I; Fujii K
    Clin Neuropathol; 2005; 24(1):8-12. PubMed ID: 15696778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100A5: a marker of recurrence in WHO grade I meningiomas.
    Hancq S; Salmon I; Brotchi J; De Witte O; Gabius HJ; Heizmann CW; Kiss R; Decaestecker C
    Neuropathol Appl Neurobiol; 2004 Apr; 30(2):178-87. PubMed ID: 15043715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
    Ozen O; Demirhan B; Altinörs N
    Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clear cell meningioma. A clinicopathologic study of a potentially aggressive variant of meningioma.
    Zorludemir S; Scheithauer BW; Hirose T; Van Houten C; Miller G; Meyer FB
    Am J Surg Pathol; 1995 May; 19(5):493-505. PubMed ID: 7726360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.
    Abramovich CM; Prayson RA
    Am J Clin Pathol; 2000 Jul; 114(1):84-92. PubMed ID: 10884803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
    Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
    Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution to malignancy in a recurrent meningioma: morphological and cytogenetic findings.
    Cerdá-Nicolás M; López-Ginés C; Barcia-Salorio J; Llombart-Bosch A
    Clin Neuropathol; 1998; 17(4):210-5. PubMed ID: 9707336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive meningioma: a tumour with high proliferating and "recurrence" potential.
    Suwa T; Kawano N; Oka H; Ito H; Kameya T
    Acta Neurochir (Wien); 1995; 136(3-4):127-31. PubMed ID: 8748841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma.
    Cobb MA; Husain M; Andersen BJ; al-Mefty O
    J Neurosurg; 1996 Jan; 84(1):85-90. PubMed ID: 8613841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computerized determination of proliferating cell nuclear antigen expression in meningiomas. A comparison with non-automated method.
    Konstantinidou A; Patsouris E; Kavantzas N; Pavlopoulos PM; Bouropoulou V; Davaris P
    Gen Diagn Pathol; 1997 Jun; 142(5-6):311-6. PubMed ID: 9228254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.